ישראל -
עברית -
Ministry of Health
פנאפט טבליות 1 מג'
megapharm ltd - iloperidone - טבליה - iloperidone 1 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
ישראל -
עברית -
Ministry of Health
פנאפט טבליות 2 מג'
megapharm ltd - iloperidone - טבליה - iloperidone 2 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
ישראל -
עברית -
Ministry of Health
פנאפט טבליות 4 מג
megapharm ltd - iloperidone - טבליה - iloperidone 4 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
ישראל -
עברית -
Ministry of Health
פנאפט טבליות 6 מג'
megapharm ltd - iloperidone - טבליה - iloperidone 6 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
ישראל -
עברית -
Ministry of Health
פנאפט טבליות 8 מג
megapharm ltd - iloperidone - טבליה - iloperidone 8 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
ישראל -
עברית -
Ministry of Health
פנאפט טבליות 10 מג'
megapharm ltd - iloperidone - טבליה - iloperidone 10 mg - iloperidone
ישראל -
עברית -
Ministry of Health
פנאפט טבליות 12 מג'
megapharm ltd - iloperidone - טבליה - iloperidone 12 mg - iloperidone
ישראל -
עברית -
Ministry of Health
גליקסמבי 10 מג 5 מג
boehringer ingelheim israel ltd. - empagliflozin; linagliptin - טבליות מצופות פילם - linagliptin 5 mg; empagliflozin 10 mg - linagliptin and empagliflozin
ישראל -
עברית -
Ministry of Health
גליקסמבי 25 מג 5 מג
boehringer ingelheim israel ltd. - empagliflozin; linagliptin - טבליות מצופות פילם - linagliptin 5 mg; empagliflozin 25 mg - linagliptin and empagliflozin
ישראל -
עברית -
Ministry of Health
ארומזין
pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.